Literature DB >> 1539162

A physiologically based kinetic model of rat and mouse gestation: disposition of a weak acid.

E J O'Flaherty1, W Scott, C Schreiner, R P Beliles.   

Abstract

A physiologically based toxicokinetic model of gestation in the rat and mouse has been developed. The model is superimposed on the normal growth curve for nonpregnant females. It describes the entire gestation period including the period of organogenesis. The model consists of uterus, mammary tissue, maternal fat, kidney, liver, other well-perfused maternal tissues, and other poorly perfused maternal tissues, embryo/fetal tissues, and yolk sac and chorioallantoic placentas. It takes into account the growth of maternal tissues such as uterus, mammary glands, fat, and liver during pregnancy, as well as growth of the conceptus. The gestation model is based on published values of organ volumes and blood flows for the rat throughout pregnancy. It is scaled to the mouse using conventional scaling procedures. Its descriptive utility has been examined with the test chemical 5,5'-dimethyloxazolidine-2,4-dione (DMO), a weak acid that is not bound measurably in plasma or tissues and is eliminated by excretion in the urine. Concentrations of DMO were monitored in maternal rat and embryo plasma and in homogenates of maternal rat muscle and whole embryo after ip administration at 9:00 AM on Day 13 of gestation. On the basis that distribution of DMO is determined solely by its pK and the pH's of body fluids, pH and excretion rate values were estimated by visual optimization of model predictions to the concentration profile. Successful prediction of concentrations of DMO in the same tissues of pregnant mice after its ip administration at 9:00 AM on Day 10 or 11 of gestation required only adjustment for pH's of mouse body fluids.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1539162     DOI: 10.1016/0041-008x(92)90194-w

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  8 in total

1.  In vitro metabolism of benzo[a]pyrene and dibenzo[def,p]chrysene in rodent and human hepatic microsomes.

Authors:  S R Crowell; S Hanson-Drury; D E Williams; R A Corley
Journal:  Toxicol Lett       Date:  2014-04-21       Impact factor: 4.372

2.  Impact of pregnancy on the pharmacokinetics of dibenzo[def,p]chrysene in mice.

Authors:  Susan Ritger Crowell; Arun K Sharma; Shantu Amin; Jolen J Soelberg; Natalie C Sadler; Aaron T Wright; William M Baird; David E Williams; Richard A Corley
Journal:  Toxicol Sci       Date:  2013-06-06       Impact factor: 4.849

Review 3.  The road to embryologically based dose-response models.

Authors:  R J Kavlock; R W Setzer
Journal:  Environ Health Perspect       Date:  1996-03       Impact factor: 9.031

Review 4.  Methods to identify and characterize developmental neurotoxicity for human health risk assessment. III: pharmacokinetic and pharmacodynamic considerations.

Authors:  D C Dorman; S L Allen; J Z Byczkowski; L Claudio; J E Fisher; J W Fisher; G J Harry; A A Li; S L Makris; S Padilla; L G Sultatos; B E Mileson
Journal:  Environ Health Perspect       Date:  2001-03       Impact factor: 9.031

5.  Integrating in vitro data and physiologically based kinetic (PBK) modelling to assess the in vivo potential developmental toxicity of a series of phenols.

Authors:  Marije Strikwold; Bert Spenkelink; Laura H J de Haan; Ruud A Woutersen; Ans Punt; Ivonne M C M Rietjens
Journal:  Arch Toxicol       Date:  2016-11-04       Impact factor: 5.153

6.  Quantitative in Vitro to in Vivo Extrapolation (QIVIVE) for Predicting Reduced Anogenital Distance Produced by Anti-Androgenic Pesticides in a Rodent Model for Male Reproductive Disorders.

Authors:  Martin Scholze; Camilla Taxvig; Andreas Kortenkamp; Julie Boberg; Sofie Christiansen; Terje Svingen; Karin Lauschke; Henrik Frandsen; Sibylle Ermler; Susan Strange Hermann; Mikael Pedersen; Anne Kruse Lykkeberg; Marta Axelstad; Anne Marie Vinggaard
Journal:  Environ Health Perspect       Date:  2020-11-25       Impact factor: 9.031

7.  Development of a Gestational and Lactational Physiologically Based Pharmacokinetic (PBPK) Model for Perfluorooctane Sulfonate (PFOS) in Rats and Humans and Its Implications in the Derivation of Health-Based Toxicity Values.

Authors:  Wei-Chun Chou; Zhoumeng Lin
Journal:  Environ Health Perspect       Date:  2021-03-17       Impact factor: 9.031

8.  PBPK Model for Atrazine and Its Chlorotriazine Metabolites in Rat and Human.

Authors:  Jerry L Campbell; Melvin E Andersen; Paul M Hinderliter; Kun Don Yi; Timothy P Pastoor; Charles B Breckenridge; Harvey J Clewell
Journal:  Toxicol Sci       Date:  2016-01-21       Impact factor: 4.849

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.